Submit Manuscript

Journal of Biological Sciences

Year: 2006 | Volume: 6 | Issue: 6 | Page No.: 1053-1058
Facebook Twitter Digg Reddit Linkedin StumbleUpon E-mail
Research Article

Comparative Immunogenicity of Commercially Available Recombinant Vaccines Against Hepatitis B in Human Urban Population of Bahawalpur District, Pakistan

Rifat-uz-Zaman

ABSTRACT

The immunogenicity profiles of the recombinant hepatitis B vaccines commercially available in Pakistan were compared to Engerix-B® in a double-blind, prospective equivalence study. A total of 744 subjects (449 male, 295 female) of different age group and professions (randomly selected) of urban areas of Bahawalpur district were included in this study. Population was divided in six different groups (children, young and adult of either sex) and each group was administered (intramuscularly) one brand of vaccine (0, 1 and 6 month schedule). Children groups were vaccinated by 10 μg while young and adults groups by 20 μg of respective vaccine. The participants had blood samples taken (3-times; at the time of second dose, one and six months after third dose). The seroprotection; geometric mean titer (mIU mL-1) of six different vaccine used, were found maximum 1880.46±12.48 with Amvax B and minimum 1790.62±18.26 with Hepa-B-vac in children group, from 1897.43±17.26 (Engirex-B) to 1815.46±12.74 (Hepa-B-vac) in young group and from 1881.75±10.97 (Amvax-B®) to 1729.82±8.85 (Hepa-B-vac) in adult group. The antibody titers <10 mIU mL-1 were found highest (3.8%) with Hepa-B-vac® and lowest (2.4%) with Amvax-B® and Hepavax-Gene®. Antibody titers 10<100, 100<1000 and >1000 mIU mL-1 were observed 14.56 (Hepa-B-vac®) to 9.1% (Amvax-B®), 40.56 (Heberbiovac) to 39.15% (Hepavax-Gene) and 48.8 (Engirex-B) to 41.61% (Hepa-B-vac), respectively. The study concluded that all the recombinant hepatitis B vaccines tested were equipotent and similar in immunogenicity to Engerix-B® in the human urban population of Bahawalpur-Pakistan.
PDF References Citation

Search

REFERENCES

  1. Safary, A. and F. Andre, 1999. Over a decade of experience with a yeast recombinant hepatitis B vaccine. Vaccine, 18: 57-67.
    PubMed
  2. Baldy, J.L., G.Z. de Lima, H.K. Morimoto, E.M. Reiche, T. Matsuo, E.D. de Mattos and L.C. Sudan, 2004. Immunogenicity of three recombinant hepatitis B vaccines administered to students in three doses containing half the antigen amount routinely used for adult vaccination. Rev. Inst. Med. Trop. Sao Paulo, 46: 103-107.
  3. Beasley, R.P. and L.Y. Hwang, 1983. Postnatal infectivity of hepatitis B surface antigen-carrier mothers. J. Infect. Dis., 147: 185-190.
  4. Bryan, J.P., P.G. Craig and L. Reyes et al., 1995. Randomized comparison of 5 and 10 microgram doses of two recombinant hepatitis B vaccines. Vaccine, 13: 978-982.
  5. Catania, G., V. Di Ciommo and C. Concato, 1996. Vaccination against hepatitis B virus in children and adolescents in a pediatric hospital. Recent Prog. Med., 87: 271-274.
  6. CDC, 2005. Transmission of hepatitis B virus among persons undergoing blood glucose monitoring in long-term-care facilities-Mississippi, North Carolina and Los Angeles County, California. MMWR, 54: 220-223.
    PubMedDirect Link
  7. Chuanfang, L., G. Yan, B. Jesper, B.H. Elizabeth and G. Christian, 2006. Effect of hepatitis B immunisation in newborn infants of mothers positive for hepatitis B surface antigen: Systematic review and meta-analysis. BMJ., 332: 328-336.
  8. Francis, D.P., S.C. Hadler and S.E. Thompson et al., 1982. The prevention of hepatitis B with vaccine. Report from the Centers for Disease Control multi-center efficacy trial among homosexual men. Ann. Intl. Med., 97: 362-366.
  9. Hadler, S.C., D.P. Francis and J.E. Maynard et al., 1986. Long-term immunogenicity and efficacy of hepatitis B vaccine in homosexual men. New Eng. J. Med., 315: 209-214.
  10. Leroux-Roels, G., B. Abraham, M. Fourneau, N. Clercq and A. Safary, 2000. A comparison of two commercial recombinant vaccines for hepatitis B in adolescents. Vaccine, 19: 937-942.
    CrossRef
  11. Martins, R.M., G. Bensabath, L.C. Arraes, L. Oliveira- Mde, J.C. Miguel, G.G. Barbosa and L.A. Camacho, 2005. Multicenter study on the immunogenicity and safety of two recombinant vaccines against hepatitis B. Mem Inst Oswaldo Cruz, 99: 865-871.
  12. Nair, P.V., J.Y. Weissman, M.J. Tong, M.W. Thursby, R.H. Paul and C.E. Henneman, 1984. Efficacy of hepatitis B immune globulin in prevention of perinatal transmission of the hepatitis B virus. Gastroenterology, 87: 293-298.
  13. Reinaldo, M.M., B. Gilberta, A.C. Luiz, O.A.L. Maria de, M.C. Juliana, B.G. Glayse and C.B.A. Luiz, 2004. Multicenter study on the immunogenicity and safety of two recombinant vaccines against hepatitis B. Mem. Inst. Oswaldo Cruz, 999: 865-871.
  14. Rifat-uz-Zaman, 2006. Prevalence of Hepatitis B and Hepatitis C viruses in human urban population of Bahawalpur District, Pakistan. J. Med. Sci., 6: 429-435.
    Direct Link
  15. Schiff, G.M., J.R. Sherwood, J.B. Zeldis and D.S. Krause, 1995. Comparative study of the immunogenicity and safety of two doses of recombinant hepatitis B vaccine in healthy adolescents. J. Adolesc. Health, 26: 12-17.
  16. Szmuness, W., C.E. Stevens, E.A. Zang, E.J. Harley and A. Kellner, 1981. A controlled clinical trial of the efficacy of the hepatitis B vaccine (Heptavax B): A final report. Hepatology, 1: 377-385.
    CrossRef
  17. American Academy of Pediatrics, 2000. Hepatitis B. In: 2000 Red Book: Report of the Committee on Infectious Diseases, Pickering, L.K. (Ed.). 25th Edn., Elk Grove Village, American Academy of Pediatrics, USA., pp: 294.
  18. Sanders, D.H., 1990. Statistics. A Fresh Approach. 4th Edn., McGraw-Hill Book Company, Auckland.

Search

Related Articles

Leave a Comment

Your email address will not be published. Required fields are marked *